Supplementary Figure S3 shows the changes in CA125 from the time she visited our hospital (April 2017) to the most recent evaluation. This case makes us ponder the following two questions: first, is chemotherapy necessary for patients with satisfactory tumor reduction achieved by surgery? Second, is maintenance therapy also suitable for patients with platinum-resistant recurrent ovarian cancer? BRCA1/2 mutation or HRD positivity may also be molecular markers of maintenance therapy for platinum-resistant recurrent ovarian cancer. This evidence concerns the gene BRCA1 and neoplasm.